Jommi, Claudio, and Marianna Cavazza. “Management of Patients Eligible for Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) Inhibitors: Economic Impact and Reform Proposals”. Global & Regional Health Technology Assessment 6, no. 1 (July 17, 2019). Accessed April 6, 2020. https://journals.aboutscience.eu/index.php/grhta/article/view/460.